Li-Cor Biotech, LLC

Li-Cor Biotech, LLC, a Lincoln, Nebraska-based for-profit limited liability partnership, manufactures and sells advanced scientific imaging systems to federal research institutions as a prime contractor, competing full-and-open with no set-aside designations across thirteen recent awards totaling $790 thousand in combined potential value.

Li-Cor Biotech's product portfolio centers on multimodal and fluorescence imaging systems. The company's core offerings include the Odyssey M Chemi/Fluor Imaging System (featuring four solid-state laser diodes at 488, 520, 685, and 785 nm wavelengths, sCMOS fluorescence detection, and CCD luminescence detection for Western blots, protein and nucleic acid detection, and tissue section analysis); the Odyssey XF and Odyssey F2 imaging bundles; the Odyssey CLX platform; and the Western Blot Imager. Representative recent awards include a $109,335.85 purchase order from the National Cancer Institute in September 2026 for an Odyssey M Chemi/Fluor system with onsite OEM-certified installation and twelve-month warranty; a $92,091.00 purchase order from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in September 2026 for an Odyssey M Chemi/Fluor bundle; a $103,579.00 purchase order from the Office of Logistics and Acquisition Operations in September 2026 for an Odyssey M multimodal imaging system to be installed in Bethesda, Maryland; and a $75,052.50 purchase order from the National Institute of Allergy and Infectious Diseases in September 2024 for an Odyssey M Fluor bundle. Li-Cor Biotech also delivers maintenance and support services—a $19,174.40 three-year support contract from Veterans Integrated Service Network 19 (completion June 2029) and a $10,280.00 one-year service agreement from Veterans Integrated Service Network 17 covering preventive maintenance and repair labor for Odyssey FC Premium equipment.

Customer concentration splits between the National Institutes of Health and the Department of Veterans Affairs. The National Cancer Institute and affiliated NIH institutes account for approximately 71% of combined potential value across five awards ($573 thousand); the VA's Veterans Health Administration (VISN 10, VISN 17, VISN 19, VISN 22) accounts for roughly 23% across six awards ($170 thousand). The Air Force Academy and the National Human Genome Research Institute round out the active customer set. All awards are classified under NAICS 334514 (Analytical Laboratory Instrument Manufacturing) or PSC 6640 (Laboratory Equipment and Supplies), with work performed primarily at the vendor's Lincoln, Nebraska facility or at customer sites.

Activity has accelerated recently: two awards in 2025 and seven in 2026 through late September. Three awards (combined potential value $305 thousand) reach ultimate completion within the next twenty-four months, creating recompete exposure. Li-Cor Biotech operates exclusively as a prime contractor with no subcontract footprint in the captured data. The vendor has secured sole-source awards from the VA and competitive awards from NIH institutes, reflecting both incumbent positioning on existing equipment platforms and competitive procurement of new systems. Across all thirteen awards, 97% of combined potential value has been obligated, indicating strong contract execution.